ATE157370T1 - Oligonukleotide mit wirkung gegen das respiratorische synzytial virus - Google Patents
Oligonukleotide mit wirkung gegen das respiratorische synzytial virusInfo
- Publication number
- ATE157370T1 ATE157370T1 AT95911046T AT95911046T ATE157370T1 AT E157370 T1 ATE157370 T1 AT E157370T1 AT 95911046 T AT95911046 T AT 95911046T AT 95911046 T AT95911046 T AT 95911046T AT E157370 T1 ATE157370 T1 AT E157370T1
- Authority
- AT
- Austria
- Prior art keywords
- oligonucleotides
- respiratory
- virus
- synzytial
- active against
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19950394A | 1994-02-18 | 1994-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE157370T1 true ATE157370T1 (de) | 1997-09-15 |
Family
ID=22737804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95911046T ATE157370T1 (de) | 1994-02-18 | 1995-02-17 | Oligonukleotide mit wirkung gegen das respiratorische synzytial virus |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0745090B1 (de) |
| JP (1) | JPH09509181A (de) |
| AT (1) | ATE157370T1 (de) |
| AU (1) | AU1878895A (de) |
| CA (1) | CA2181546A1 (de) |
| DE (1) | DE69500618D1 (de) |
| WO (1) | WO1995022553A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997014792A2 (en) * | 1995-10-17 | 1997-04-24 | Hybridon, Inc. | Oligonucleotides with anti-respiratory syncytial virus activity |
| JP2000506384A (ja) * | 1996-02-15 | 2000-05-30 | ナショナル インスティチューツ オブ ヘルス | ＲＮａｓｅ Ｌ アクチベーター及びＲＳＶ感染の治療に有効なアンチセンスオリゴヌクレオチド |
| US6214805B1 (en) * | 1996-02-15 | 2001-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
| US5989912A (en) | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US5831069A (en) * | 1997-03-04 | 1998-11-03 | South Alabama Medical Science Foundation | Antisense oligonucleotides against nonstructural proteins NS1 and NS2 of respiratory syncytial virus and uses thereof |
| US20030203356A1 (en) * | 2002-01-22 | 2003-10-30 | The Cleveland Clinic Foundation | RNase L activator-antisense complexes |
| WO2003064625A2 (en) | 2002-02-01 | 2003-08-07 | Sequitur, Inc. | Oligonucleotide compositions with enhanced efficiency |
| US10131904B2 (en) | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
| US8796443B2 (en) | 2008-09-22 | 2014-08-05 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| IL265674B2 (en) | 2010-03-24 | 2024-05-01 | Phio Pharm Corp | Rana disorder in cutaneous and fibrotic symptoms |
| US9095504B2 (en) | 2010-03-24 | 2015-08-04 | Rxi Pharmaceuticals Corporation | RNA interference in ocular indications |
| EP3077050B1 (de) | 2013-12-04 | 2020-10-21 | Phio Pharmaceuticals Corp. | Verfahren zur behandlung von wundheilung mit chemisch modifizierten oligonukleotiden |
| KR102506169B1 (ko) | 2014-09-05 | 2023-03-08 | 피오 파마슈티칼스 코프. | Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법 |
| KR20180026739A (ko) | 2015-07-06 | 2018-03-13 | 알엑스아이 파마슈티칼스 코포레이션 | 슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자 |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| US11021707B2 (en) | 2015-10-19 | 2021-06-01 | Phio Pharmaceuticals Corp. | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA |
| EP3612152A4 (de) | 2017-04-19 | 2021-02-17 | Phio Pharmaceuticals Corp. | Topische verabreichung von nukleinsäureverbindungen |
| KR20230107609A (ko) * | 2020-11-12 | 2023-07-17 | 머크 샤프 앤드 돔 엘엘씨 | 항-호흡기 세포융합 바이러스 (rsv) 항체 세포-기반 역가 검정 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ244820A (en) * | 1991-10-25 | 1994-01-26 | Isis Pharmaceuticals Inc | Oligonucleotide inhibitor of epstein-barr virus. |
-
1995
- 1995-02-17 AT AT95911046T patent/ATE157370T1/de not_active IP Right Cessation
- 1995-02-17 AU AU18788/95A patent/AU1878895A/en not_active Abandoned
- 1995-02-17 DE DE69500618T patent/DE69500618D1/de not_active Expired - Lifetime
- 1995-02-17 EP EP95911046A patent/EP0745090B1/de not_active Expired - Lifetime
- 1995-02-17 WO PCT/US1995/002080 patent/WO1995022553A1/en not_active Ceased
- 1995-02-17 CA CA002181546A patent/CA2181546A1/en not_active Abandoned
- 1995-02-17 JP JP7521953A patent/JPH09509181A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69500618D1 (de) | 1997-10-02 |
| EP0745090A1 (de) | 1996-12-04 |
| AU1878895A (en) | 1995-09-04 |
| CA2181546A1 (en) | 1995-08-24 |
| JPH09509181A (ja) | 1997-09-16 |
| WO1995022553A1 (en) | 1995-08-24 |
| EP0745090B1 (de) | 1997-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE157370T1 (de) | Oligonukleotide mit wirkung gegen das respiratorische synzytial virus | |
| TWI317735B (en) | Methods and compositions for treating hepatitis c virus | |
| WO2003063771A3 (en) | N4-acylcytosine nucleosides for treatment of viral iinfections | |
| BR9812232A (pt) | Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico | |
| BR9913935A (pt) | Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo | |
| IL143512A (en) | Azabicycloalkanes, pharmaceuticals including them and their use in the manufacture of drugs for the prevention or treatment of infection by the immunodeficiency virus | |
| NO954217L (no) | Guanosinrike antivirus-oligonukleotider | |
| WO2001032153A3 (en) | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues | |
| DK0662157T3 (da) | Præparater og fremgangsmåde til behandling af Hepatitis C-virus-associerede sygdomme | |
| IL130931A0 (en) | Small molecules useful in the treatment of inflammatory disease | |
| BR0111195A (pt) | Uso de b-l-2'-desoxi-nucleosìdeos no tratamento de infecção por vìrus de hepatite delta | |
| WO2001010456A3 (en) | Peptides that block viral infectivity and methods of use thereof | |
| CY1106178T1 (el) | 2’- υποκατεστημενα 1,1’-διφαινυλο-2-καρβοξαμιδια, μεθοδος για την παρασκευη τους, η χρηση τους ως φαρμακου καθως και φαρμακευτικα παρασκευασματα που τα πepιεχουν | |
| KR970704768A (ko) | 사람 면역결핍증 바이러스의 증식을 억제하는 화합물 및 방법(Compounds and Methods for Inhibiting Propagation of Human Immunoefficiency Virus) | |
| CA2380924A1 (en) | Compositions for treating viral infections, and methods therefor | |
| ZA991029B (en) | Composition and methods for treatment of hiv infections. | |
| WO2000038660A3 (de) | Verwendung von bisphosphonaten zur prophylaxe und zur behandlung von infektiösen prozessen | |
| EP0328924A3 (de) | Thienotriazoldiazepinverbindungen und deren pharmazeutische Anwendungen | |
| NO931246L (no) | Sammensetninger for behandling av infeksjon og sykdom foraarsaket av hepatites b virus (hbv) | |
| BR0209145A (pt) | Vacina contra varìola | |
| WO1997014792A3 (en) | Oligonucleotides with anti-respiratory syncytial virus activity | |
| FR2693202B1 (fr) | Polymères amphiphiles hydrosolubles, leur procédé de préparation et leur application comme épaississant. | |
| EP1110556A4 (de) | Präventiv- und/oder heilmittel für multiples organversagen | |
| NO965468D0 (no) | Farmasöytisk preparat for forhindring og/eller behandling av virale infeksjoner og eventuelle inflammasjoner, så vel som en behandlingsmetode derfor | |
| WO2001045642A3 (en) | Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |